Efficacy and safety of Duloxetine versus paroxetine for adults' depression: A meta-analysis

Chinese Journal of Evidence-Based Medicine

Volumn 12, Issue 3, 2012, Pages 320-325

  Chen, Cheng ^a   Xu, Wei Ping ^a   Huang, Ying ^a   Xu, Ting Juan ^a   Wei, Wei ^a   Hu, Shi Lian ^a   Yan, Guang ^a  

^a ANHUI MEDICAL UNIVERSITY   (China)

Author keywords

Depression; Duloxetine; Meta analysis; Paroxetine; Randomized controlled tiral; Systematic review

Indexed keywords

DULOXETINE; PAROXETINE;

ARTICLE; DEPRESSION; DRUG EFFICACY; DRUG SAFETY; ECG ABNORMALITY; HUMAN; META ANALYSIS; PUBLICATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); SOMNOLENCE; SYSTEMATIC REVIEW;

EID: 84860146003     PISSN: 16722531     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Greden JF. The burden of disease for treatment-resistant depression. J Clin Psychiatry, 2001, 62 Suppl 16: 26-31.
2. Perahia DG, Quail D, Desaiah D, et al. Switching to duloxetine in selective serotonin reuptake inhibitor non- and partial-responders: effects on painful physical symptoms of depression. J Psychiatr Res, 2009, 43(5): 512-518.
3. Knadler MP, Lobo E, Chappell J, et al. Duloxetine: clinical pharmacokinetics and drug interactions. Clin Pharmacokinet, 2011, 50(5): 281-294.
4. Cipriani A, Furukawa TA, Salanti G, et al. Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis. Lancet, 2009, 373(9665): 746-758.
5. Cremers TI, Rea K, Bosker FJ, et al. Augmentation of SSRI effects on serotonin by 5-HT2C antagonists: mechanistic studies. Neuropsychopharmacology, 2007, 32(7): 1550-1557.
6. Gueorguieva R, Mallinckrodt C, Krystal JH. Trajectories of depression severity in clinical trials of duloxetine: insights into antidepressant and placebo responses. Arch Gen Psychiatry, 2011, 68(12): 1227-1237.
7. Maier W, Philipp M. Improving the assessment of severity of depressive states: a reduction of the Hamilton Depression Scale. Pharmacopsychiatry, 1985, 18: 114-115.
8. Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials, 1996, 17(1): 1-12.
9. Detke MJ, Wiltse CG, Mallinckrodt CH, et al. Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial. Eur Neuropsychopharmacol, 2004, 14(6): 457-470.
10. Perahia DG, Wang F, Mallinckrodt CH, et al. Duloxetine in the treatment of major depressive disorder: a placebo- and paroxetine-controlled trial. Eur Psychiatry, 2006, 21(6): 367-378.
11. Lee P, Shu L, Xu X, et al. Once-daily duloxetine 60 mg in the treatment of major depressive disorder: multicenter, double-blind, randomized, paroxetine-controlled, non-inferiority trial in China, Korea, Taiwan and Brazil. Psychiatry Clin Neurosci, 2007, 61(3): 295-307.
12. Chinese Source.
13. Chinese Source.
14. Chinese Source.
15. Bymaster FP, Dreshfield-Ahmad LJ, Threlkeld PG, et al. Comparative affinity of duloxetine and venlafaxine for serotonin and norepinephrine transporters in vitro and in vivo, human serotonin receptor subtypes, and other neuronal receptors. Neuropsychopharmacology, 2001, 25(6): 871-880.
16. Carter NJ, McCormack PL. Duloxetine: a review of its use in the treatment of generalized anxiety disorder. CNS Drugs, 2009, 23(6): 523-541.
17. Wohlreich MM, Mallinckrodt CH, Prakash A, et al. Duloxetine for the treatment of major depressive disorder: safety and tolerability associated with dose escalation. Depress Anxiety, 2007, 24(1): 41-52.
18. Trivedi MH, Desaiah D, Ossanna MJ, et al. Clinical evidence for serotonin and norepinephrine reuptake inhibition of duloxetine. Int Clin Psychopharmacol, 2008, 23(3): 161-169.
19. Schueler YB, Koesters M, Wieseler B, et al. A systematic review of duloxetine and venlafaxine in major depression, including unpublished data. Acta Psychiatr Scand, 2011, 123(4): 247-265.
20. Skljarevski V, Zhang S, Desaiah D, et al. Duloxetine versus placebo in patients with chronic low back pain: a 12-week, fixed-dose, randomized, double-blind trial. J Pain, 2010, 11(12): 1282-1290.
21. Fishbain DA, Hall J, Meyers AL, et al. Does pain mediate the pain interference with sleep problem in chronic pain? Findings from studies for management of diabetic peripheral neuropathic pain with duloxetine. J Pain Symptom Manage, 2008, 36(6): 639-647.
22. Kluge M, Schüssler P, Steiger A, et al. Duloxetine increases stage 3 sleep and suppresses rapid eye movement (REM) sleep in patients with major depression. Eur Neuropsychopharmacol, 2007, 17(8): 527-531.
23. Thase ME, Tran PV, Wiltse C, et al. Cardiovascular profile of duloxetine, a dual reuptake inhibitor of serotonin and norepinephrine. J Clin Psychopharmacol, 2005, 25(2): 132-140.
24. Gahimer J, Wernicke J, Yalcin I, et al. A retrospective pooled analysis of duloxetine safety in 23,983 subjects. Curr Med Res Opin, 2007, 23(1): 175-184.
25. Zhang L, Chappell J, Gonzales CR, et al. QT effects of duloxetine at supratherapeutic doses: a placebo and positive controlled study. J Cardiovasc Pharmacol, 2007, 49(3): 146-153.
26. Xue F, Strombom I, Turnbull B, et al. Treatment with duloxetine in adults and the incidence of cardiovascular events. J Clin Psychopharmacol, 2012, 32(1): 23-30.
27. Wernicke J, Lledó A, Raskin J, et al. An evaluation of the cardiovascular safety profile of duloxetine: findings from 42 placebo-controlled studies. Drug Saf, 2007, 30(5): 437-455.